期刊文献+

间苯三酚对顽固性心力衰竭患者血浆BNP和D-二聚体的影响

下载PDF
导出
摘要 目的通过间苯三酚治疗顽固性心力衰竭,观察患者血浆BNP和D-二聚体含量的变化,探讨间苯三酚对顽固性心力衰竭患者的治疗价值。方法顽固性心力衰竭的患者82例,随机分为观察组和对照组,每组41例,观察组给予间苯三酚200 mg加入5%葡萄糖溶液250 ml中静脉滴注,疗程15 d;对照组给予酚妥拉明20 mg加入0.9%氯化钠溶液250 ml中静脉滴注,疗程15 d;测定患者治疗前后的血浆BNP和D-二聚体含量变化。结果 2组治疗前比较差异无统计学意义(P>0.05),2组血浆BNP和D-二聚体治疗后较治疗前明显降低,差异有统计学意义(P<0.05)。试验组治疗后血浆BNP和D-二聚体较对照组明显降低,差异有统计学意义(P<0.05)。结论间苯三酚可降低顽固性心力衰竭患者血浆BNP和D-二聚体指标,对顽固性心力衰竭患者有效。
出处 《河北医药》 CAS 2014年第21期3277-3279,共3页 Hebei Medical Journal
  • 相关文献

参考文献11

  • 1匡晓晖,韩明华.慢性心力衰竭的抗凝治疗[J].医学综述,2013,19(4):652-656. 被引量:11
  • 2Dempfle CE. The use of soluble fibrin in evaluating the acute andchronic hypercoagulable state. Thromb Haemost, 1999,82 : 673-683.
  • 3Heinrich J, Shulte H, Schonfeld R. Association of variables of co-agula- tion, fibrinolysis and acute phase with atherosclerosis in eoro-nary and pe- ripheral arteries and those arteries supplying the brain. Thromb Haemost, 1995,73:374-379.
  • 4Sudoh T, Kangawa K, Minamion N, et al. A natriuretie peptide inporeine brain. Nature, 1988,32:78-81.
  • 5谢瑞芹,崔炜,郝玉明,刘凡,李保华,吴金凤.猪心肌缺血再灌注过程中体表和冠脉内心电图改变与梗死面积的关系[J].河北医科大学学报,2008,29(2):184-187. 被引量:1
  • 6Lin KW, Huang AM, Tu HY, et al. Phloroglucinols inhibit chemical medi- ators and xanthine oxidase, and protect cisplatin-induced cell death by re- ducing reactive oxygen species in normal human urothelial and bladder cancer cells. J Agric Food Chem,2009,57:8782.
  • 7Li "IT, Zhang YS, He L, et al. Protective effect of phloroglucinol against myocardial ischaemiareperfusion injury is related to inhibition of my- eloperoxidase activity and inflammatory cell infiltration. Clin Exp Pharma- col Physio1,2011,38 :27.
  • 8陈风宇,牛晓亚.辨证治疗充血性心力衰竭96例[J].河南中医药学刊,2000,15(6):7-8. 被引量:6
  • 9毛拥军,张春华,刘松,陈祥鸿.脑钠肽与充血性心力衰竭的治疗[J].中华心血管病杂志,2004,32(9):855-857. 被引量:47
  • 10Chong AY, BLann AD, Patel J,et al. Endothelial dysfunction anddamage in congestive heart failure : relation of flow-mediated dila-tion to circulat- ing endothelial ceils, plasma indexes of endothelialdamage, and brain natriuretic peptide. Circulation ,2004,110 : 1794-1798.

二级参考文献63

  • 1高伟,王士雯,赵玉生.脑钠肽前体N末端片段在心血管病研究应用中的现状[J].中华心血管病杂志,2004,32(8):759-761. 被引量:65
  • 2Sagnella GA.Mearement and significance of circulating natriuretic peptides in cardiovascular disease.Clin Sci,1998,95:519-529.
  • 3Hystad ME,Geiran OR,Attramadal H,et al.Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure.Acta Physiol Scand,2001,171:395-403.
  • 4Goto T,Takase H,Toriyama T,et al.Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure.Heart,2003,89:1303-1307.
  • 5Hobbs RE,Miller LW,Bott-Silverman C,et al.Hemodynamic effects of a single Intravenous Injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.Am J Cardiol,1996,78:896
  • 6Mills RM,LeJemtel TH,Horton DP,et al.Sustainded hemodynamic effects of an Infusion of nesiritide(human B-type natriuretic peptide)in heart failure.J Am Coll Cardiol,1999,34:155-162.
  • 7Colucci WS,Elkayam U,Horton DP,et al.Intravenous nesiritide,a natriuretic peptide,in the treatment of decompensated congestive heart failure.N Engl J Med,2000,343:896.
  • 8Burger AJ,Elkayam U,Neibaur MT,et al.Comparison of the occurrence of ventricular arrhythmias in patients with acutely decornpensated congestive heart failure receiving dobutamine versus nesiritide therapy.Am J Cardiol,2001,88 :35-39.
  • 9Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure-a randomized controlled trial.JAMA,2002,287:1531-1535.
  • 10U.S.Food and Drug Administration.The Food and Drug Administration( FDA)has approved Natrecor(nesiritide)Injection for the treatment of acute congestive heart failure(CHF).New York:FDA Talk Paper,2001.T01-T36.

共引文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部